Related Experiment Video

Updated: Oct 12, 2025

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR
08:30

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR

Published on: May 16, 2012

24.7K

miR-33b-3p Acts as a Tumor Suppressor by Targeting DOCK4 in Prostate Cancer

Yu Mei1, Kai Li1, Zhicheng Zhang2

  • 1School of Life Science and Technology, Harbin Institute of Technology, Harbin, China.

Frontiers in Oncology
|November 22, 2021
PubMed

Insights

MicroRNA miR-33b-3p acts as a tumor suppressor in prostate cancer, inhibiting metastasis by targeting DOCK4. Enhancing miR-33b-3p may improve treatment for metastatic prostate cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Prostate cancer often progresses to metastatic castration-resistant prostate cancer despite androgen-deprivation therapy.
  • Identifying novel therapeutic targets is crucial for managing advanced prostate cancer.

Purpose of the Study:

  • To investigate the role of miR-33b-3p in prostate cancer metastasis.
  • To identify the molecular targets and therapeutic potential of miR-33b-3p.

Main Methods:

  • Analysis of miR-33b-3p expression in prostate cancer tissues and correlation with patient survival.
  • In vitro studies on prostate cancer cell migration and invasion.
  • In vivo metastasis models in mice.
  • Validation of DOCK4 as a direct miR-33b-3p target.
  • Investigation of bortezomib's effect on miR-33b-3p expression and prostate cancer cell behavior.

Main Results:

  • miR-33b-3p expression is significantly reduced in prostate cancer tissues and correlates with poor survival.
  • Overexpression of miR-33b-3p inhibits prostate cancer cell migration and invasion, while inhibition promotes these processes.
  • miR-33b-3p suppresses lung and lymph node metastasis in vivo.
  • DOCK4 is a direct target of miR-33b-3p, and its restoration rescues miR-33b-3p's inhibitory effects.
  • Bortezomib downregulates miR-33b-3p, and miR-33b-3p overexpression enhances bortezomib's efficacy against metastasis.

Conclusions:

  • miR-33b-3p functions as a tumor suppressor in prostate cancer by inhibiting metastasis through targeting DOCK4.
  • Enhancing miR-33b-3p expression represents a potential therapeutic strategy to improve treatment outcomes for metastatic prostate cancer, particularly in combination with proteasome inhibitors.
Keywords:
DOCK4metastasismiR-33b-3pprostate cancerproteasome inhibitor

More Related Videos

miRNA Expression Analyses in Prostate Cancer Clinical Tissues11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

11.0K
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.8K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
22.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.1K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
36.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K